Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00094146 · ClinicalTrials.gov registry record · Phase 2
Sandostatin LAR® Depot in Patients With Primary Insulin Hypersecretion (PIH) and at Least Moderate Obesity
A Phase 2 study of Obesity and Primary Insulin Hypersecretion, sponsored by Novartis.
- Completed
- Registry status
- Phase 2
- Development phase
- 160
- Enrollment target
- 3
- Study locations
NCT00094146 is a Phase 2 study of Obesity and Primary Insulin Hypersecretion that has completed, run by Novartis. The registered enrollment target is 160 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (80% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT00094146, a Phase 2 study of Obesity and Primary Insulin Hypersecretion, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 160 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study is in patients with at least moderate obesity (Body Mass Index \[BMI\] \> 30 kg/m2 or approximately 30 or more pounds overweight) and who also produce too much insulin (insulin stores sugar as fat). Sandostatin LAR® Depot suppresses insulin, and is being developed to help with weight loss in people who find it hard to lose weight on their own because they produce too much insulin. The main purpose of the study is to find the lowest dose of Sandostatin LAR® Depot that safely helps overweight people lose weight. The study will also compare weight loss in obese patients who receive one of three different dosages of Sandostatin LAR Depot or placebo.
Conditions Studied
Interventions
- DRUG Sandostatin LAR Depot
Study Locations (3)
Louisiana
- New Orleans Center for Clinical Research - New Orleans
Tennessee
- University of Tennessee - Memphis
Wisconsin
- University of Wisconsin Beers-Murphy Clinical Nutrition Clinic - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2002-01 |
| Est. Completion | 2002-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00094146
The ClinicalTrials.gov registry entry for NCT00094146 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (80% lower). The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 1 intervention - of which Sandostatin LAR Depot is the first listed.
NCT00094146 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Louisiana, Tennessee, Wisconsin.
Frequently Asked Questions
What is clinical trial NCT00094146 about?
NCT00094146 is a clinical study titled "Sandostatin LAR® Depot in Patients With Primary Insulin Hypersecretion (PIH) and at Least Moderate Obesity". This study is in patients with at least moderate obesity (Body Mass Index \[BMI\] \> 30 kg/m2 or approximately 30 or more pounds overweight) and who also produce too much insulin (insulin stores sugar as fat). Sandostatin LAR® Depot suppresses insulin, and is being developed to help with weight loss...
What is the current status of trial NCT00094146?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 160 participants. The study started on 2002-01. Estimated completion is 2002-12.
What conditions does trial NCT00094146 study?
This clinical trial studies the following conditions: Obesity, Primary Insulin Hypersecretion.
What interventions are being tested in trial NCT00094146?
The interventions under investigation include: Sandostatin LAR Depot (DRUG).
Who is sponsoring clinical trial NCT00094146?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00094146 being conducted?
This trial has 3 study locations across Louisiana, Tennessee, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
RECRUITING · Phase 2
-
Convergent Mechanisms Underlying Reprometabolic Syndrome in Women
RECRUITING · Phase 2
-
Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity
RECRUITING · Phase 2
-
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
RECRUITING · Phase 2
-
Pharmacological and Behavioral Treatment After Bariatric Surgery
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.